Results: Of 17,377 participants, 1,773 (10.2%) reported having type 2 diabetes. Earlier age at menarche was associated with type 2 diabetes, compared to median menarche age 13 years, after multiple adjustment (p for linear trend <0.0001; Table). The asso- ciation of earlier age at menarche was more pronounced with stroke among women with diabetes (p for linear trend 0.02; Table). In women with diabetes, younger age at menarche was associated with higher CRP levels (least square mean ± standard error: 5.6mg/L ±1.1 for age at menarche 10 years, 5.0±1.1 for 11 years, 3.3±1.1 for 12 years, 3.6±1.1 for 13 years, 3.3±1.1 for 14 years; p for linear trend 0.04). Discussion: Earlier age at menarche was associated with type 2 diabetes. Among women with diabetes, earlier age at menarche was associated with stroke complication and chronic inflamma- tion among young and middle-aged women living with diabetes in the U.S. Diabetes Research and Clinical Practice 186S (2022) 109280 https://doi.org/10.1016/j.diabres.2022.109280 IDF21-0426 Carbamylated LDL and soluble LOX-1 – potential serum biomarkers for coronary artery disease in type 2 diabetes mellitus T. Stankova a , G. Delcheva a , K. Stefanova a , R. Staynova b , K. Chalova c , A. Maneva a a Medical University of Plovdiv, Faculty of Pharmacy, Department of Medical Biochemistry, Plovdiv, Bulgaria b Medical University of Plovdiv, Faculty of Pharmacy, Department of Pharmaceutical Sciences, Plovdiv, Bulgaria c Medical University of Plovdiv, Faculty of Medicine, Department of Obstetrics and Gynaecology, Plovdiv, Bulgaria Background: Carbamylated low-density lipoprotein (cLDL) is the most abundant modified LDL isoform in human blood, but it has been investigated only in the context of chronic kidney dis- ease since uremia provides a favourable chemical environment for this posttranslational modification. However, it has been dis- covered that the proinflammatory enzyme myeloperoxidase catalyses an alternative urea-independent mechanism of car- bamylation. Most of the proatherogenic properties of cLDL are mediated by the scavenger lectin-like oxidized LDL receptor-1 (LOX-1). LOX-1 has been delineated as a critical player in vascular inflammation and in atherosclerotic plaque formation, destabi- lization, erosion and rupture. The cLDL-LOX-1 interaction triggers prooxidative and proinflammatory responses. Moreover, LOX-1 has also been identified as a receptor for C-reactive protein (CRP), a classic acute-phase reactant widely used in the clinical practice as a cardiovascular risk biomarker. The soluble form of LOX-1 (sLOX-1) reflects the expression of the membrane receptor and it has recently been suggested as a biomarker of vascular dis- eases. It is well-established that type 2 diabetes mellitus (T2DM) is a prominent risk factor for coronary artery disease (CAD) and inflammation is involved in the pathogenesis of both T2DM and atherosclerosis. However, the possible role and relationships between cLDL, sLOX-1 and CRP in T2DM with and without CAD have not been investigated yet. Aim: To explore the possible role of cLDL and sLOX-1 as poten- tial biomarkers for CAD in T2DM patients and to evaluate the cor- relations between serum cLDL, sLOX-1 and high-sensitivity-CRP (hs-CRP). Method: The serum levels of cLDL, sLOX-1 and hs-CRP were measured by ELISA in 44 heathy controls, 67 patients with uncomplicated T2DM and 36 diabetic subjects complicated by CAD but without renal impairments. Results: Patients with uncomplicated T2DM had significantly higher serum levels of both cLDL and hs-CRP than the healthy controls, but lower in comparison to T2DM + CAD subjects. In contrast, there was no significant difference in sLOX-1 concentra- tions between T2DM patient and the healthy volunteers, but T2DM + CAD cohort had higher serum levels of sLOX-1 compared both to the control and uncomplicated T2DM groups. The recei- ver-operating characteristic analysis showed that cLDL and sLOX-1 had a significant potential to identify CAD among the dia- betic patients with diagnostic sensitivity and specificity similar to those of hs-CRP. Elevated serum levels of cLDL and sLOX-1 were associated with a higher risk of CAD development among T2DM subjects (OR 4.07; 95% CI: 1.71 – 9.69, p = 0.001 and OR 2.82; 95% CI: 1.22 – 6.57, p = 0.014, respectively). Furthermore, the level of cLDL correlated positively and significantly with hs-CRP (r = 0.345, p = 0.039) and tended to correlate positively with sLOX-1 (r = 0.317, p = 0.059) only in T2DM + CAD subjects. Discussion: In conclusion, a positive feedback might exist between cLDL, CRP and LOX-1 and the interplay between them might be involved in the development of CAD in diabetic patients. The present study also elucidates the potential of cLDL and sLOX- 1 as biomarkers for the diagnosis and risk assessment of CAD among T2DM population. Diabetes Research and Clinical Practice 186S (2022) 109281 https://doi.org/10.1016/j.diabres.2022.109281 IDF21-0451 Using NT-ProBNP for risk stratification in individuals with dia- betes: a retrospective study from a diabetes centre S. Radha a , R. Khaled a , H. Sabbour b , N. Lessan a a Imperial College London Diabetes Centre, Research Institute, Abu Dhabi, United Arab Emirates b Cleveland Clinic Abu Dhabi, Heart ＆ Vascular Institute, Abu Dhabi, United Arab Emirates Background: Patients with diabetes are at higher risk for developing cardiac and renal complications. N-terminal (NT)- pro hormone BNP (NT-proBNP) is a sensitive biomarker for early detection of cardiac and renal failure. Aim: In this study, we investigated associations of high and low NT-proBNP levels with clinical and metabolic parameters among patients with diabetes. Method: Patients with diabetes with available NT-ProBNP mea- surement and with an eGFR >45 were identified from ICLDC elec- tronic database. Demographic and clinical parameters were extracted. Patients were grouped based on serum NT-proBNP levels;  125 pg/ml (NT-low) and > 125 pg/ml (NT-high). Statistical analysis were done in SPSS 26.0; results are presented as median (IQR). Results: Out of 590 patients (56.1% females; 76.6% Emiratis), 209 (35.4%) had NT-ProBNP> 125 pg/ml. Clinical and demographic 24 diabetes research and clinical practice 186S (2022) 109240